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Recent research has resumed the pivotal significance of cognitive
impairments for the development of psychosis spectrum disorders,
proposing a shift in focus extending from psychotic symptoms
as the key hallmarks (1, 2). Cognitive deficits are of particular
interest as they precede the onset of psychosis by many years
in the absence of any psychotic symptom and thus providing
valuable predictions about the longitudinal course (3). Recog-
nizing cognitive disturbances as the main promoter may allow
early detection of the illness and might also lead to adequate and
effective treatment.
Neuroscientific brain imaging techniques have essentially
helped putting the attention back on cognition. In this research
topic, we aimed at emphasizing the tremendous relevance of cog-
nitive impairments for the early stages of psychosis and their neu-
robiological correlates as measured with a broad variety of brain
imaging modalities such as electro- and magnetoencephalogra-
phy, structural, functional, and resting state magnetic resonance
imaging, near-infrared spectroscopy, and proton magnetic reso-
nance spectroscopy. The topic begins with articles emphasizing
the evidence of cognitive deficits in patients with schizophrenia,
first-episode psychosis, and in persons from the general population
with psychosis-like experiences and whether they are mirrored in
brain signals as measured by functional near-infrared spectroscopy
or structural magnetic resonance imaging (4–7). Further works
review the underlying neuropharmacological mechanisms of cog-
nitive impairments by focusing on different established domains
and discuss potential drug targets for cognitive enhancement treat-
ments (8, 9). This research topic also highlights the significance
of the N -methyl-d-aspartate receptor for the development of psy-
chosis and how glutamatergic metabolites are related to symptoms
and cognitive function in clinical samples, suggesting promising
new target pathways for the treatment of psychosis (10–12). Fur-
thermore, electrophysiological modeling strategies in animals (13)
and healthy subjects (14–16) are presented, which might help to
establish neurobiological markers not only for the treatment of
cognitive deficits but also for the prediction of psychosis and
the development of preventive treatment schemes. The largest
part of this issue unifies theoretical and experimental evidence
reflecting the immense potential of computational neuroscience
for shedding new light on the neurophysiological mechanisms
underlying psychosis in general and on the formation of specific
psychopathological signs and symptoms in particular. It starts with
a normative consideration of psychotic symptoms as a result of
aberrant encoding of precision embedded with predictive coding
framework (17). The topic ends up with several computational
modeling approaches and reviews addressing the relation between
neural network properties, pharmacological challenges, cognition,
and genetic risk (18–22).
This issue is intended to provide a state-of-the-art cognitive
perspective to consider developing psychosis and will serve as
useful framework for further investigations inferring pathophys-
iological mechanisms of psychosis. Such sorts of analyses might
help to predate the onset of psychosis in terms of abnormal brain
signals and to improve and develop new therapeutic scenarios. We
would like to thank all the authors and reviewers for their valuable
contributions, as well as the Editorial Office for their help in the
editing process.
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